相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Measuring the Performance of Markers for Guiding Treatment Decisions
Holly Janes et al.
ANNALS OF INTERNAL MEDICINE (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Daniel J. Toft et al.
MOLECULAR ENDOCRINOLOGY (2011)
An accelerated pathway for targeted cancer therapies
Mark McClellan et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Accrual to Cancer Clinical Trials in the Era of Molecular Medicine
Richard L. Schilsky
SCIENCE TRANSLATIONAL MEDICINE (2011)
Evaluating Performance of a Decision Support System to Improve Methotrexate Pharmacotherapy in Children and Young Adults With Cancer
Erin Dombrowsky et al.
THERAPEUTIC DRUG MONITORING (2011)
Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence
P. D. Mozley et al.
ANNALS OF ONCOLOGY (2010)
Phase III Clinical Trial Development: A Process of Chutes and Ladders
David M. Dilts et al.
CLINICAL CANCER RESEARCH (2010)
Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology
Michael L. Maitland et al.
CLINICAL CANCER RESEARCH (2010)
Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis
Michael L. Maitland
CLINICAL CANCER RESEARCH (2010)
Systems Biology and Pharmacology
J. M. Berg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006
Michaela A. Dinan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot
Ann A. Lazar et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Genetic and Clinical Predictors for Breast Cancer Risk Assessment and Stratification Among Chinese Women
Wei Zheng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Tackling the widespread and critical impact of batch effects in high-throughput data
Jeffrey T. Leek et al.
NATURE REVIEWS GENETICS (2010)
Performance of Common Genetic Variants in Breast-Cancer Risk Models.
Sholom Wacholder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Other Paradigms: Better Treatments Are Identified by Better Trials The Value of Randomized Phase II Studies
Manish R. Sharma et al.
CANCER JOURNAL (2009)
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies
R. Bruno et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial
S. Mook et al.
EUROPEAN JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Personalizing Cancer Care: American Society of Clinical Oncology Presidential Address 2009
Richard L. Schilsky
JOURNAL OF CLINICAL ONCOLOGY (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1
Wei Zheng et al.
NATURE GENETICS (2009)
OUTLOOK The microeconomics of personalized medicine: today's challenge and tomorrow's promise
Jerel C. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Quantitative Disease, Drug, and Trial Models
Jogarao V.S. Gobburu et al.
Annual Review of Pharmacology and Toxicology (2008)
Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy
Jeffrey S. Barrett et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2008)
Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer
Keith A. Baggerly et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Basal-like breast cancer: A critical review
Emad A. Rakha et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the national oncologic PET registry
Bruce E. Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer
Simon N. Stacey et al.
NATURE GENETICS (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Participation in clinical trials as viewed by the patient: Understanding cultural and emotional aspects which influence choice
Chiara Catania et al.
ONCOLOGY (2008)
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22-33
Bert Gold et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy
Sam E. Day et al.
NATURE MEDICINE (2007)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
Theodore G. Karrison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer
Simon N. Stacey et al.
NATURE GENETICS (2007)
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
David J. Hunter et al.
NATURE GENETICS (2007)
Genome-wide association study identifies novel breast cancer susceptibility loci
Douglas F. Easton et al.
NATURE (2007)
The prospects for personalized medicine in drug development and drug therapy
J. Woodcock
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006
V. A. Bhattaram et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Economics of new oncology drug development
Joseph A. DiMasi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Target practice: oncology drug development in the era of genomic medicine
Richard L. Schilsky
CLINICAL TRIALS (2007)
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Jan Bogaerts et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Patients' decision-making process regarding participation in phase I oncology research
Manish Agrawal et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
Marc Buyse et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
X chromosomal abnormalities in basal-like human breast cancer
AL Richardson et al.
CANCER CELL (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
EP Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cancer trial enrollment after state-mandated reimbursement
CP Gross et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Evaluating markers for selecting a patient's treatment
S Xiao et al.
BIOMETRICS (2004)
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196
JA Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making
JVS Gobburu et al.
CLINICAL PHARMACOKINETICS (2001)
分享论文
